Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPX 
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CMPX (5-star) is a STRONG-BUY. BUY since 32 days. Simulated Profits (12.46%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.91
1 Year Target Price $12.91
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 229.28% | Avg. Invested days 36 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 681.14M USD | Price to earnings Ratio - | 1Y Target Price 12.91 |
Price to earnings Ratio - | 1Y Target Price 12.91 | ||
Volume (30-day avg) 9 | Beta 1.3 | 52 Weeks Range 1.27 - 4.86 | Updated Date 10/26/2025 |
52 Weeks Range 1.27 - 4.86 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.14% | Return on Equity (TTM) -51.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 504311568 | Price to Sales(TTM) 439.25 |
Enterprise Value 504311568 | Price to Sales(TTM) 439.25 | ||
Enterprise Value to Revenue 109.28 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 171572498 | Shares Floating 100795496 |
Shares Outstanding 171572498 | Shares Floating 100795496 | ||
Percent Insiders 11.42 | Percent Institutions 62.54 |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer. Founded to advance best-in-class antibody therapeutics. It has focused on developing its pipeline through its StitchMabs and Trispecifics platforms.
Core Business Areas
- Antibody Therapeutics Development: Focuses on discovering and developing antibody-based therapeutics for cancer treatment.
- StitchMabs Platform: A platform technology for creating bispecific and multispecific antibodies.
- Trispecifics Platform: A technology platform to develop trispecific antibodies with enhanced functionalities.
Leadership and Structure
Key leadership includes Thomas Schuetzle (CEO). The company operates with a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- CTx-471: A fully human agonistic antibody targeting CD137, currently in clinical development. Competitors include other companies developing CD137 agonists, such as Bristol Myers Squibb and Roche.
- StitchMabs Platform: A technology for the discovery of next-generation therapies to overcome key limitations in current oncology treatment. Competitors for this platform concept are biotech firms with innovative antibody engineering capabilities such as Regeneron.
Market Dynamics
Industry Overview
The oncology therapeutics market is characterized by high growth and intense competition. It is driven by the increasing incidence of cancer globally and advancements in immunotherapy and targeted therapies.
Positioning
Compass Therapeutics focuses on differentiated antibody therapeutics, aiming to address unmet needs in cancer treatment. Their platforms offer a competitive advantage in designing novel antibody formats.
Total Addressable Market (TAM)
The oncology drug market is projected to reach hundreds of billions of dollars. Compass Therapeutics aims to capture a share of this market with its pipeline of antibody therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary Antibody Platforms (StitchMabs and Trispecifics)
- Clinical-Stage Assets (CTx-471)
- Experienced Management Team
- Focus on Immunooncology
Weaknesses
- Limited Financial Resources Compared to Larger Pharma
- Dependence on Clinical Trial Success
- Early-Stage Pipeline
- Lack of Approved Products
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion of Pipeline Through New Targets
- Positive Clinical Trial Results
- Increased Adoption of Immunotherapy
Threats
- Clinical Trial Failures
- Competition from Established Players
- Regulatory Hurdles
- Patent Expiry
Competitors and Market Share
Key Competitors
- BMY
- RHHBY
- MRK
Competitive Landscape
Compass Therapeutics is a smaller player in a competitive market dominated by larger pharmaceutical companies. Its advantage lies in its proprietary antibody platforms and focus on novel immuno-oncology targets.
Growth Trajectory and Initiatives
Historical Growth: The company's growth depends on successful clinical development and potential partnering deals.
Future Projections: Future growth is tied to clinical trial results and potential for commercialization or partnering of its assets. Analyst estimates were not available.
Recent Initiatives: Focus on advancing CTx-471 through clinical trials and expanding pipeline through platform technologies.
Summary
Compass Therapeutics is a clinical-stage biopharmaceutical company with proprietary antibody platforms targeting cancer. The company's strength lies in its innovative technology and focus on immuno-oncology. A lack of readily available financial data and the inherent risks of clinical-stage development remain important to consider. Success is highly dependent on advancing its clinical programs and securing partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Third-Party Financial Data Providers
Disclaimers:
This analysis is based on available public information and is not financial advice. Market share estimates are approximate and may vary. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.